Main news

Polypill Shows LDL-Lowering Advantage in High-risk Primary Prevention Patients: VULCANO
Polypill Shows LDL-Lowering Advantage in High-risk Primary Prevention Patients: VULCANO Key Takeaways The CNIC (Centro Nacional de Investigaciones Cardiovasculares) polypill contains acetylsalicylic acid (100 mg), atorvastatin (30 mg or 40 mg), and ramipril (2.5 mg, 5 mg, or 10 mg), and is the only polypill for cardiovascular disease (CVD) currently marketed in European countries.


Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association The American Heart Association, in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, and weight) and health factors (cholesterol, blood pressure, and glucose control) that contribute to cardiovascular health.


Editorial Activity

cardiology book

ESC/EACTS to Review Left Main Revascularization Guidance Patrice Wendling
ESC/EACTS to Review Left Main Revascularization Guidance Patrice Wendling The European Society of Cardiology and European Association for Cardiothoracic Surgery (ESC/EACTS) have announced they will review their joint recommendations for left main coronary artery disease in light of emerging data.



World Heart Day
World Heart Day On World Heart Day, 29 September 2020, we’re asking the world to Use Heart to beat CVD ... for your loved ones, society and you.



Major Indexing Service Calls Out Cardiology Journals for Self-Citation
Major Indexing Service Calls Out Cardiology Journals for Self-Citation More than 70% of the citations in one journal were to other papers in that journal. Another published a single paper that cited nearly 200 other articles in the journal.


Novel Lipid Therapies: 5 Things to Know
Novel Lipid Therapies: 5 Things to Know The development of novel pharmacotherapies targeting low-density lipoprotein (LDL), lipoprotein a, and triglycerides (TG) to help prevent patients' risk of atherosclerotic cardiovascular disease (ASCVD) has accelerated during the past decade.


COVID-19 and cardiovascular diseases: main aspects
COVID-19 and cardiovascular diseases: main aspects Igor S. Yavelov MD, PhD, Professor of cardiology


Administration of patients during and after a coronavirus pandemic. Interview with professor Mekhman N. Mamedov.
Administration of patients during and after a coronavirus pandemic. Interview with professor Mekhman N. Mamedov. Dear Colleagues! On April 27, 2021, at the initiative of the Indonesian Society of Cardiology, an online meeting was held with one of the leading experts of Russia in the cardiology, Professor Mekhman N Mamedov.